Celldex Therapeutics, Inc. (CLDX) Forms $2.36 Double Bottom; Athenex (ATNX) Shorts Down By 19.71%

August 27, 2017 - By Vivian Currie

Celldex Therapeutics, Inc. (CLDX) formed double bottom with $2.24 target or 5.00% below today’s $2.36 share price. Celldex Therapeutics, Inc. (CLDX) has $302.89M valuation. The stock increased 0.85% or $0.02 on August 25, reaching $2.36. About 889,734 shares traded. Celldex Therapeutics, Inc. (NASDAQ:CLDX) has declined 20.62% since August 27, 2016 and is downtrending. It has underperformed by 37.32% the S&P500.

Athenex Incorporated (NASDAQ:ATNX) had a decrease of 19.71% in short interest. ATNX’s SI was 475,300 shares in August as released by FINRA. Its down 19.71% from 592,000 shares previously. With 133,500 avg volume, 4 days are for Athenex Incorporated (NASDAQ:ATNX)’s short sellers to cover ATNX’s short positions. The SI to Athenex Incorporated’s float is 2.74%. The stock decreased 2.00% or $0.32 on August 25, reaching $15.65. About 57,825 shares traded. Athenex Inc (NASDAQ:ATNX) has 0.00% since August 27, 2016 and is . It has underperformed by 16.70% the S&P500.

Athenex, Inc. is an oncology pharmaceutical firm focused on the development and commercialization of therapies for cancer diseases and supportive therapies. The company has market cap of $893.05 million. The Company’s technology platform is organized into three categories, including Oral Absorption Platform, Src Kinase Inhibitors and Symptom Therapeutics. It currently has negative earnings. The Firm offers Oraxol, an oral formulation of paclitaxel; Orateacan, an oral formulation of Irinotecan; Oradoxel, an oral formulation of Docetaxel, and an oral formulation of Topotecan for the treatment of various types of cancers.

Among 12 analysts covering Celldex Therapeutics (NASDAQ:CLDX), 7 have Buy rating, 0 Sell and 5 Hold. Therefore 58% are positive. Celldex Therapeutics had 20 analyst reports since August 11, 2015 according to SRatingsIntel. The stock has “Outperform” rating by Cowen & Co on Tuesday, March 8. The firm has “Buy” rating given on Wednesday, August 9 by H.C. Wainwright. The stock has “Buy” rating by H.C. Wainwright on Tuesday, August 1. The firm earned “Buy” rating on Friday, February 26 by Cantor Fitzgerald. The rating was maintained by Cowen & Co with “Buy” on Tuesday, June 6. Jefferies maintained the stock with “Hold” rating in Tuesday, August 9 report. The firm has “Market Perform” rating by Leerink Swann given on Monday, March 7. The rating was maintained by Oppenheimer with “Outperform” on Tuesday, August 11. The stock of Celldex Therapeutics, Inc. (NASDAQ:CLDX) has “Buy” rating given on Tuesday, August 11 by Brean Capital. Oppenheimer downgraded the shares of CLDX in report on Monday, March 7 to “Perform” rating.